Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin at 78.8%
Operating margin was 78.8% in Q2 FY2026. On a trailing-twelve-month basis it was 27.2%. Over 3 fiscal years it narrowed by 36963.4 pp.
Context
- Operating margin widened in 1 of the last 2 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 2 analysts of 17.7% for the fiscal year ending Dec 2026, up from -40274.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 78.8%— QoQ
- Last fiscal yearDec 2025
- -40274.4%— YoY
- LTMJun 2026
- 27.2%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +5711.1 pp | — |
| 1 year | — | +40292.2 pp | — |
| 3 years | -36963.4 pp | +38837.1 pp | +75800.5 pp |
| 5 years | +40197.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -40274.4%
- Year-over-year change
- —
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -40274.4% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | -64098.8% | -60787.7pp |
| FY2022 | 2022-12-31 | -3311.1% | -1128.9pp |
| FY2021 | 2021-12-31 | -2182.2% | — |
Operating Margin vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's LTM Jun 2026 operating margin of 27.2% is the highest of the 2 companies compared; the peer median is -79.0%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 27.2% | — | -36963.4 pp | |
| LTM Mar 2026 | -79.0% | +535.1 pp | — | |
OKUROnKure Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ATNM) | -79.0% | +535.1 pp | — | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.14M | 1.03M | 81K | 0 | 90K |
| Cost of Revenue | 524K | 0 | 0 | 811K | 0 |
| Gross Profit | 620K | 1.03M | 81K | (811K) | 90K |
| Gross Margin | 54.2% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 17.51M | 23.14M | 38.67M | 30.05M | 21.12M |
| Selling, General & Admin | 8.08M | 12M | 13.33M | 12.08M | 15.21M |
| Operating Expenses | 25.58M | 35.13M | 52M | 41.31M | 36.34M |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| EBITDA | (24.25M) | (32.32M) | (48.03M) | (37.43M) | (33.07M) |
| EBITDA Margin | -2119.8% | -3137.7% | -59293.8% | — | -36740.0% |
| Operating Income | (24.96M) | (34.1M) | (51.92M) | (42.12M) | (36.25M) |
| Operating Margin | -2182.2% | -3311.1% | -64098.8% | — | -40274.4% |
| Interest Income | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Income Before Tax | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Pre-Tax Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Net Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| EPS (Basic) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| EPS (Diluted) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| Weighted Avg Shares | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M |
| Weighted Avg Shares (Diluted) | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.